Skip to main content
Caplight Logo









Nilo Therapeutics

Nilo Therapeutics

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.nilotx.com/

Last Round

Series A

Oct 8, 2025

Total Funding Raised

$101M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Nilo Therapeutics is a biotechnology company that develops a class of medicines that harness neural circuits to restore immune homeostasis in disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyneuro-immunologydrug discoveryautoimmune diseasevagus nerveimmunomodulatorypreclinical researchbioelectronic medicineneural circuitsinflammatory diseasebiotech startuptherapeutic pipelinedrug licensingimmune homeostasisneuro-immune

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nilo Therapeutics Comparables

Compare Nilo Therapeutics with similar companies based on industry and business-model similarity.

Nilo Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
GSK plc
74%
Kallyope
70%
Nimbus Therapeutics
67%

Nilo Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 8, 2025

Key People

Founding team and executive leadership

Kim Seth

President Chief Executive Officer

Executive Team

Nilo Therapeutics Investors

Notable investors and investment history

Nilo Therapeutics investors
InvestorRounds
The Column GroupSeries A
DCVC BioSeries A
Gates Family FoundationSeries A
Lux CapitalSeries A
Gates FoundationSeries A
Bill & Melinda Gates FoundationSeries A
Alexandria Venture InvestmentsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 8, 2025

    $101M Series A round completed.

  • Oct 8, 2025

    Kim Seth, Ph.D. appointed as Chief Executive Officer and Board director.

Nilo Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nilo Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nilo Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range39
Year Founded2024
Last FundingOct 8, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?